| abstract |
The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity for the a-subunit of the IL-2 receptor for use as an immunotherapeutic agent. The present invention also relates to an immunoconjugate comprising said mutated IL-2 polypeptide, a polynucleotide molecule encoding a mutant IL-2 polypeptide or an immunoconjugate, and a vector and host cell comprising said polynucleotide molecule. The invention also relates to a method of producing a mutant IL-2 polypeptide or immunoconjugate, a pharmaceutical composition comprising the same, and uses thereof. |